Last reviewed · How we verify
Naropin (ROPIVACAINE)
Naropin (generic name: ROPIVACAINE) is a Amide Local Anesthetic Small molecule drug developed by Fresenius Kabi. It is currently FDA-approved (first approved 1996) for Anesthesia for cesarean section, Local anesthesia, Major Nerve Block for Surgery.
Naropin is a small molecule used as a local anesthetic. It has been studied in various clinical trials for conditions such as pain, postoperative pain, and adolescent idiopathic scoliosis, among others.
At a glance
| Generic name | ROPIVACAINE |
|---|---|
| Sponsor | Fresenius Kabi |
| Drug class | Amide Local Anesthetic |
| Target | Sodium channel protein type 5 subunit alpha |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
- Anesthesia for cesarean section
- Local anesthesia
- Major Nerve Block for Surgery
- Regional Anesthesia for Labor Pain
- Regional Anesthesia for Postoperative Pain
- Regional Anesthesia for Surgery
Common side effects
- Anaesthetic complication
- Anaphylactic shock
- Local anaesthetic systemic toxicity
- Maternal exposure during delivery
- Cardiac arrest
- Delayed recovery from anaesthesia
- Generalised tonic-clonic seizure
- Therapeutic product effect prolonged
- Cauda equina syndrome
- Respiratory depression
- Hypotension
- Peripheral nerve injury
Key clinical trials
- Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection (NA)
- Intranasal Dexmedetomidine for Prevention of Intrapartum Fever (NA)
- Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Knee Arthroplasty (PHASE4)
- Intranasal Dexmedetomidine for Postpartum Depression Prevention (NA)
- External Oblique Intercostal Block Versus Transversus Abdominis Plane Combined With Rectus Sheath Block on Postoperative Pain in Laparoscopic Radical Gastrectomy (NA)
- A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China. (PHASE3)
- OMT for Adhesive Capsulitis (PHASE4)
- Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naropin CI brief — competitive landscape report
- Naropin updates RSS · CI watch RSS
- Fresenius Kabi portfolio CI
Frequently asked questions about Naropin
What is Naropin?
Naropin (ROPIVACAINE) is a Amide Local Anesthetic drug developed by Fresenius Kabi, indicated for Anesthesia for cesarean section, Local anesthesia, Major Nerve Block for Surgery.
What is Naropin used for?
Naropin is indicated for Anesthesia for cesarean section, Local anesthesia, Major Nerve Block for Surgery, Regional Anesthesia for Labor Pain, Regional Anesthesia for Postoperative Pain.
Who makes Naropin?
Naropin is developed and marketed by Fresenius Kabi (see full Fresenius Kabi pipeline at /company/fresenius-kabi).
What is the generic name of Naropin?
ROPIVACAINE is the generic (nonproprietary) name of Naropin.
What drug class is Naropin in?
Naropin belongs to the Amide Local Anesthetic class. See all Amide Local Anesthetic drugs at /class/amide-local-anesthetic.
When was Naropin approved?
Naropin was first approved on 1996.
What development phase is Naropin in?
Naropin is FDA-approved (marketed).
What are the side effects of Naropin?
Common side effects of Naropin include Anaesthetic complication, Anaphylactic shock, Local anaesthetic systemic toxicity, Maternal exposure during delivery, Cardiac arrest, Delayed recovery from anaesthesia.
What does Naropin target?
Naropin targets Sodium channel protein type 5 subunit alpha and is a Amide Local Anesthetic.
Related
- Drug class: All Amide Local Anesthetic drugs
- Target: All drugs targeting Sodium channel protein type 5 subunit alpha
- Manufacturer: Fresenius Kabi — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Anesthesia for cesarean section
- Indication: Drugs for Local anesthesia
- Indication: Drugs for Major Nerve Block for Surgery
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing